Search results for "Concomitant"

showing 10 items of 248 documents

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E a…

2009

Background:Two parallel randomized phase 2 trialswere performed to choose the optimal way of combining cetuximab with gemcitabine in the first-line treatment of elderly (CALC1-E) and adult PS2 (CALC1-PS2) patients with advanced NSCLC. Methods: Stage IV or IIIB NSCLC patients, aged ≥70 years with PS 0–2 for CALC1-E or aged <70 with PS2 for CALC1-PS2, not selected for EGFR expression,were eligible. Patients were randomized to concomitant (gemcitabine, for a maximum of 6 cycles, plus cetuximab until progression) or sequential (gemcitabine, for a maximum of 6 cycles, followed by cetuximab) strategy. A selection design, with 1-year survival rate as the primary endpoint, was applied, requiring 58…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsAdolescentSettore MED/06 - Oncologia MedicaCetuximabNSCLCAntibodies Monoclonal HumanizedDeoxycytidinelaw.inventionYoung AdultRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerPS2 patientSurvival analysisAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryClinical trialTreatment OutcomeOncologyConcomitantPatient ComplianceFemalebusinessElderly patientmedicine.drug
researchProduct

The mutual relationship between heart failure and atrial fibrillation

2020

Atrial fibrillation (AF) and heart failure (HF) are evolving epidemies, together responsible for substantial human suffering and health-care expenditure. The simultaneous co-hexistence of the two conditions is associated with mortality rates higher than those observed in individuals with only one or none of them. Patients with concomitant HF and AF suffer from even worse symptoms and poorer prognosis, yet evidence-based evaluation and management of this group of patients is lacking. In this review, we evaluate the common mechanisms for the development of AF in HF patients and vice versa, focusing on the evidence for potential treatment strategies. Recent data have suggested that these patie…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAdverse outcomesbusiness.industryMortality ratelcsh:Rheart failurelcsh:MedicineAtrial fibrillationArrhythmia-induced cardiomyopathymedicine.diseaseAtrial fibrillationHeart failure.Risk FactorsHeart failureConcomitantmedicineHumansTreatment strategyBest evidenceCardiology and Cardiovascular MedicineIntensive care medicinebusinessHealthcare system
researchProduct

P123 Inhaled corticosteroid plus long-acting β2-agonist therapy is overused in the treatment of patients with chronic obstructive pulmonary disease: …

2015

Rationale Inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) therapy is indicated for different patient groups with chronic obstructive pulmonary disease (COPD) in the USA and Europe. In the previous version of the Global initiative for chronic Obstructive Lung Disease (GOLD) recommendations, the use of ICS plus LABA therapy was restricted to patients with severe and very severe lung-function impairment and frequent exacerbations, with overtreatment in milder patient populations well documented. The current GOLD document recommends the use of ICS plus LABA maintenance therapy for patients in categories C and D. Methods We present post hoc analyses from the two pivotal 1-year TO…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDCombination therapyPost hocbusiness.industrymedicine.drug_classPulmonary diseasemedicine.diseaseObstructive lung diseaseMaintenance therapyInternal medicineConcomitantmedicinePhysical therapyCorticosteroidbusinessThorax
researchProduct

S61 Analysis of the efficacy and safety of the combination of tiotropium + olodaterol in patients with COPD by previous usage of inhaled corticostero…

2015

Rationale Tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist (both administered once daily), have been studied as a once-daily combination. Two Phase III studies have demonstrated that T+O significantly improved lung function and symptoms over T and O monotherapy treatments in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). 1 During these studies, patients were allowed to continue existing treatment with inhaled corticosteroids (ICS); this analysis was conducted to determine the effects of study treatment in patients receiving or not receiving ICS as reported at baseline. Methods A total of 5162 patients we…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDeducation.field_of_studybusiness.industryInhalerPopulationOlodaterolArea under the curveMuscarinic antagonistmedicine.diseaseGastroenterologySurgerychemistry.chemical_compoundchemistryInternal medicineConcomitantmedicineRespiratory systembusinesseducationmedicine.drugThorax
researchProduct

Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism

2015

Background Deep vein thrombosis (DVT) and pulmonary embolism (PE) are connected with a poor outcome in cancer patients. We aimed to investigate the impact of cancer on the effectiveness of cardiac Troponin I (cTnI) to predict right ventricular dysfunction (RVD) in acute PE. Methods We retrospectively analyzed the data of 182 patients with confirmed PE. PE patients were subdivided into two groups: (i) with concomitant active cancer disease or history of cancer, and (ii) without known cancer. Receiver operating characteristic (ROC) curves with area under the curve (AUC) was calculated for cTnI predicting RVD and related cut-off levels for both groups. Results Thirty-seven PE patients (20.3%) …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyReceiver operating characteristicbusiness.industryDeep veinArea under the curveCancerGeneral Medicinemedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureOncologyConcomitantInternal medicineTroponin Icardiovascular systemmedicineCardiologybusinessThoracic Cancer
researchProduct

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

2019

Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Study aim: To evaluate the impact of a previous radical prostatectomy (RP) on the outcome of 223Ra therapy in mCRPC patients. The primary prostate tumor left untreated could progress during 223Ra treatment. Materials and methods: mCRPC symptomatic patients treated with 223Ra were enrolled. Luteinizing Hormone-Releasing Hormone analogue was maintained. No other anticancer therapy was given. 223Ra was administered i.v. at the dose of 55 kBq/kg every 4 weeks for 6 cycles. Patients were stratified according to previous RP or not. Hematological toxicity w…

Radium-223Malemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic AgentsBone NeoplasmsSettore MED/24 - UrologiaPrimary tumor03 medical and health sciencesProstate cancer0302 clinical medicineProstateRadium-222medicineHumansAgedProstatectomyRadiotherapybusiness.industryProstatectomyProstateChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadical prostatectomyPrimary tumorSurvival AnalysisRadiation therapyProstatic Neoplasms Castration-Resistantmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisConcomitantDisease ProgressionCastration resistant prostate cancerNeoplasm GradingRadiopharmaceuticalsbusinessmedicine.drugHormoneFollow-Up StudiesRadiumUrologic oncology
researchProduct

Ranitidine-Induced Confusion with Concomitant Morphine

1988

Ranitidinebusiness.industryAnesthesiaConcomitantMorphineMedicinePharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsmedicine.symptombusinessConfusionmedicine.drugDrug Intelligence &amp; Clinical Pharmacy
researchProduct

Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry

2017

OBJECTIVE In view of low prevalence rates, diabetes is discussed as a protective factor for the occurrence of Takotsubo syndrome (TTS). Furthermore, it was associated with improved outcome in a small single-center analysis. Therefore, this study assessed the prevalence and prognostic relevance of concomitant diabetes in TTS. RESEARCH DESIGN AND METHODS A total of 826 patients with TTS were enrolled in an international, multicenter, registry-based study (eight centers in Italy and Germany). All-cause mortality was compared between patients with diabetes and patients without diabetes, and the independent predictive value of diabetes was evaluated in multivariate regression analysis. RESULTS …

Research designMalemedicine.medical_specialtyDiabetic CardiomyopathiesEndocrinology Diabetes and MetabolismMEDLINEPrevalenceProtective factorDiabetes Takotsubo030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsTakotsubo CardiomyopathyDiabetes mellitusInternal medicineGermanyInternal MedicineDiabetes MellitusPrevalenceMedicineHumans030212 general & internal medicineRegistriesAgedAdvanced and Specialized NursingTakotsubo syndromebusiness.industryMortality rateMiddle Agedmedicine.diseasePrognosisItalyConcomitantFemalebusiness
researchProduct

Current status of laboratory and imaging diagnosis of neonatal necrotizing enterocolitis

2018

Abstract Necrotizing enterocolitis continues to be a devastating disease process for very low birth weight infants in Neonatal Intensive Care Units. The aetiology and pathogenesis of necrotizing enterocolitis are not definitively understood. It is known that necrotizing enterocolitis is secondary to a complex interaction of multiple factors that results in mucosal damage, which leads to intestinal ischemia and necrosis. Advances in neonatal care, including resuscitation and ventilation support technology, have seen increased survival rates among premature neonates and a concomitant detection in the incidence of this intestinal disease. Diagnosis can be difficult, and identifying infants at …

Resuscitationmedicine.medical_specialtyReviewDiseaseImaging03 medical and health sciences0302 clinical medicineEnterocolitis NecrotizingNecrotizing enterocolitis030225 pediatricsIntensive careDiagnosismedicineNecrotizing enterocolitiHumans030212 general & internal medicineIntensive care medicineBiomarkers Diagnosis Imaging Necrotizing enterocolitis Newborn Enterocolitis Necrotizing Humans Infant Newborn Pediatrics Perinatology and Child Healthbusiness.industryIncidence (epidemiology)Infant Newbornlcsh:RJ1-570lcsh:PediatricsBiomarkerGeneral MedicineNewbornmedicine.diseaseLow birth weightConcomitantNecrotizing enterocolitisEtiologymedicine.symptombusinessBiomarkersDiagnosi
researchProduct

Die Chronisch rekurrierende multifokale Osteomyelitis (CRMO)*: - Teil 2 Klinisch-radiologisch-histopathologische Studie zum kindlich-jugendlichen „Be…

2001

We report about the juvenile and adolescent pelvic type of CRMO in 7 girls and 4 boys. The results show from solitary up to 7 pelvic lesions (average 3 lesions) predominantly in the acetabular and paraacetabular region (sometimes with hip joint effusion as a sign for concomitant coxitis).Tc99m-bone-scan is helpful to evaluate exactly the pattern of bone affection. We find 3 stages of an primarily chronic, non-purulent osteomyelitis going along with a "plasma-cell-sclerotic process", leading to a Garre-type sclerosing end-stage, which probably heals after some years spontaneously, projecting on clinical symptoms and radiological appearance. The concomitant coxitis ("sympathetic coxitis") is …

SAPHO syndromemedicine.medical_specialtyBone diseasebusiness.industryOsteomyelitisChronic recurrent multifocal osteomyelitismedicine.diseaseSurgeryEl NiñoConcomitantPediatrics Perinatology and Child HealthOrthopedic surgerymedicineOsteitisbusinessKlinische Pädiatrie
researchProduct